Cargando…

AQP4-IgG NMOSD, MOGAD, and double-seronegative NMOSD: is it possible to depict the antibody subtype using magnetic resonance imaging?

Background There is clinical and radiological overlap among demyelinating diseases. However, their pathophysiological mechanisms are different and carry distinct prognoses and treatment demands. Objective To investigate magnetic resonance imaging (MRI) features of patients with myelin-oligodendroc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fragoso, Diego Cardoso, Salles, Luana Michelli Oliveira de Paula, Pereira, Samira Luisa Apóstolos, Callegaro, Dagoberto, Sato, Douglas Kazutoshi, Rimkus, Carolina de Medeiros
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Thieme Revinter Publicações Ltda. 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10306980/ https://www.ncbi.nlm.nih.gov/pubmed/37379865 http://dx.doi.org/10.1055/s-0043-1768669

Ejemplares similares

Comparative study of AQP4-NMOSD, MOGAD and seronegative NMOSD: a single-center Belgian cohort
por: Dauby, Solène, et al.
Publicado: (2021)

The effect of smoking on MRI lesion resolution in NMOSD-AQP4 and MOGAD
por: Berhanu, David, et al.
Publicado: (2023)

Demystifying MOGAD and Double Seronegative NMOSD Further With IL-6 Blockade
por: Yong, Kok Pin, et al.
Publicado: (2021)

Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD
por: Dinoto, Alessandro, et al.
Publicado: (2022)

Impaired response of blood neutrophils to cell-death stimulus differentiates AQP4-IgG-seropositive NMOSD from MOGAD
por: Schroeder-Castagno, Maria, et al.
Publicado: (2022)

NMOSD and MOGAD Dual Positivity: An Extremely Rare Phenomenon
por: Agarwal, Ayush, et al.
Publicado: (2022)

The use of OCT in good visual acuity MOGAD and AQP4-NMOSD patients; with and without optic neuritis
por: Roca-Fernández, A, et al.
Publicado: (2021)

Myelitis features and outcomes in CNS demyelinating disorders: Comparison between multiple sclerosis, MOGAD, and AQP4-IgG-positive NMOSD
por: Fadda, Giulia, et al.
Publicado: (2022)

Targeting B cells to modify MS, NMOSD, and MOGAD: Part 2
por: Graf, Jonas, et al.
Publicado: (2020)

Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1
por: Graf, Jonas, et al.
Publicado: (2020)

Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD
por: Derdelinckx, Judith, et al.
Publicado: (2021)

Plasma Complement 3 and Complement 4 Are Promising Biomarkers for Distinguishing NMOSD From MOGAD and Are Associated With the Blood-Brain-Barrier Disruption in NMOSD
por: Lin, Liuyu, et al.
Publicado: (2022)

Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD
por: Kim, Sohyeon, et al.
Publicado: (2023)

AQP4‐IgG positive paraneoplastic NMOSD: A case report and review
por: Ding, Manqiu, et al.
Publicado: (2021)

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab
por: Paul, Friedemann, et al.
Publicado: (2023)

CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications
por: Kaneko, Kimihiko, et al.
Publicado: (2018)

The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
por: Sen, Sedat, et al.
Publicado: (2022)

Peripapillary hyper-reflective ovoid mass-like structures (PHOMS) in AQP4-IgG-positive neuromyelitis optica spectrum disease (NMOSD) and MOG-IgG-associated disease (MOGAD)
por: Gernert, Jonathan A., et al.
Publicado: (2022)

Area postrema syndrome: Frequency, criteria, and severity in AQP4-IgG–positive NMOSD
por: Shosha, Eslam, et al.
Publicado: (2018)

Helicobacter pylori infection may influence prevalence and disease course in myelin oligodendrocyte glycoprotein antibody associated disorder (MOGAD) similar to MS but not AQP4-IgG associated NMOSD
por: Malli, Chaithra, et al.
Publicado: (2023)

Pain in NMOSD and MOGAD: A Systematic Literature Review of Pathophysiology, Symptoms, and Current Treatment Strategies
por: Asseyer, Susanna, et al.
Publicado: (2020)

Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD
por: Jitprapaikulsan, Jiraporn, et al.
Publicado: (2020)

A case report on recurrent area postrema syndrome in AQP4-IgG-positive NMOSD
por: Shrestha, Ramesh, et al.
Publicado: (2022)

Different clinical phenotypes of AQP4-IgG positive NMOSD in two first degree relatives
por: Ssemmanda, Salvatore, et al.
Publicado: (2023)

Microstructural visual system changes in AQP4-antibody–seropositive NMOSD
por: Oertel, Frederike C., et al.
Publicado: (2017)

COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in multiple sclerosis, AQP4-antibody NMOSD and MOGAD
por: Yeo, Tianrong, et al.
Publicado: (2022)

An Abnormally High Neutrophil-to-Lymphocyte Ratio Is Not an Independent Outcome Predictor in AQP4-IgG-Positive NMOSD
por: Carnero Contentti, Edgar, et al.
Publicado: (2021)

Longitudinal Evaluation of Serum MOG-IgG and AQP4-IgG Antibodies in NMOSD by a Semiquantitative Ratiometric Method
por: Bollo, Luca, et al.
Publicado: (2021)

Paraneoplastic NMOSD associated with EG junction adenocarcinoma expressing unprotected AQP4
por: Sudo, Atsushi, et al.
Publicado: (2018)

Neuromyelitis-optica-Spektrum-Erkrankungen (NMOSD) und Anti-Myelin-Oligodendrozyten-Glykoprotein-Antikörper-assoziierte Erkrankungen (MOGAD)
por: Seifert-Held, Thomas
Publicado: (2022)

Normal volumes and microstructural integrity of deep gray matter structures in AQP4+ NMOSD
por: Finke, Carsten, et al.
Publicado: (2016)

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD
por: Prain, Kerri, et al.
Publicado: (2019)

Treatment and outcome of aquaporin-4 antibody–positive NMOSD: A multinational pediatric study
por: Paolilo, Renata Barbosa, et al.
Publicado: (2020)

Elevated serum levels of bone morphogenetic protein-9 are associated with better outcome in AQP4-IgG seropositive NMOSD
por: Masuda, Hiroki, et al.
Publicado: (2023)

Adverse Events in NMOSD Therapy
por: Giglhuber, Katrin, et al.
Publicado: (2022)

An elderly female case of AQP4 and GFAP double-positive NMOSD coexisting with ovarian teratoma
por: Yang, Jiahui, et al.
Publicado: (2023)

Assessing attacks and treatment response rates among adult patients with NMOSD and MOGAD: Data from a nationwide registry in Argentina
por: Contentti, Edgar Carnero, et al.
Publicado: (2021)

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD
por: Shi, Mingchao, et al.
Publicado: (2022)

NMOSD IgG Impact Retinal Cells in Murine Retinal Explants
por: Wolf, Hannah Nora, et al.
Publicado: (2023)

Spontaneous remission lasting more than a decade in untreated AQP4 antibody–positive NMOSD
por: Pandit, Lekha, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q6tvcgpj2bphgfvk6eeqf36505